

Ilaria Gandoglia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9302567/publications.pdf>

Version: 2024-02-01

17
papers

504
citations

933447

10
h-index

996975

15
g-index

18
all docs

18
docs citations

18
times ranked

816
citing authors

#	ARTICLE	IF	CITATIONS
1	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. <i>EBioMedicine</i> , 2022, 80, 104042.	6.1	54
2	A peculiar case of internal carotid dissection: “do not forget Eagle’s syndrome”. <i>Neurological Sciences</i> , 2021, 42, 2527-2529.	1.9	2
3	Response to: “MuSK-positive myasthenia may be triggered not only by SARS-CoV-2”. <i>European Journal of Neurology</i> , 2021, 28, e82-e83.	3.3	1
4	SARS-CoV-2 and Stroke Characteristics. <i>Stroke</i> , 2021, 52, e117-e130.	2.0	51
5	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117385.	0.6	9
6	The importance of thinking about Guillain-Barré syndrome during the COVID-19 pandemic: a case with pure dysautonomic presentation. <i>Journal of NeuroVirology</i> , 2021, 27, 662-665.	2.1	15
7	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , 2021, 72, 103581.	6.1	184
8	Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection. <i>European Journal of Neurology</i> , 2021, 28, 3537-3539.	3.3	39
9	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. <i>Neurotherapeutics</i> , 2020, 17, 200-207.	4.4	39
10	A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1765-1788.	2.0	7
11	In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. <i>Immunology Letters</i> , 2017, 181, 109-115.	2.5	16
12	Teriflunomide treatment reduces B cells in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e403.	6.0	28
13	Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1969-1973.	3.3	9
14	Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity. <i>Journal of Neuroimmunology</i> , 2014, 275, 54-55.	2.3	0
15	Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma?. <i>Journal of Neuroimmunology</i> , 2014, 275, 218.	2.3	0
16	Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. <i>BMC Neurology</i> , 2014, 14, 103.	1.8	10
17	Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 665-672.	4.1	29